Loading…
Loading…
How are you thinking about the time line? I know you mentioned sort of a relatively quick turnaround
What fraction of MABs typically require these chronic NHP studies and what fraction were getting an FDA waiver?
whether there's any step you can take proactively over the next twelve months to further de-risk your supply chain there
Any cancellation payment benefit in the fourth quarter? Do you expect one to come through in 2025?
Are you considering revisiting sort of that premium price positioning you plan to charge for Envision, just given current market conditions
Just wondering beyond tariffs in China, how to think about the 60 bps haircut?
Can you just provide some context and the degree to which that that's unlocking some conversations for you
how much of Hologic's OUS revenue is made in the US and how much of US revenue was dependent on manufacturing overseas
any comments on the stranded costs associated with the mega trial that you said is now pushed to 2026